#AANAM - Lecanemab Safely Lowers Amyloid Clumps in Alzheimer's
One-year data from a Phase 2 trial's extension showed safe and rapid, sustained drops in beta-amyloid levels in early stage patients.| Alzheimer's News Today
One-year data from a Phase 2 trial's extension showed safe and rapid, sustained drops in beta-amyloid levels in early stage patients.| Alzheimer's News Today
Lindsey Shapiro is a science writer for Alzheimer's News Today with a PhD in neuroscience. She covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Just-released full data from the Phase 3 Clarity AD trial show lecanemab can significantly slow dementia in early-onset Alzheimer’s patients.| Alzheimer's News Today
The FDA approved Leqembi (lecanemab-irmb), the second of a new category of medications approved for Alzheimer’s disease that target the fundamental pathophysiol| U.S. Food and Drug Administration
The immunotherapy Leqembi, formerly BAN2401, is now FDA-approved for slowing cognitive decline in patients with Alzheimer's disease.| Alzheimer's News Today
Read a summary of the causes Alzheimer's disease, inclouding neurofibrillary tangles, inflammation, vascular and environmental factors, genetics and aging.| Alzheimer's News Today
Category archive page for News.| Alzheimer's News Today
Learn more about Alzheimer's disease, the most common cause of dementia and an irreversible, progressive neurological disorder.| Alzheimer's News Today
